Kim, Tae-Yong
Han, Hye Sook
Lee, Keun-Wook
Zang, Dae Young
Rha, Sun Young
Park, Young Iee
Kim, Jin-Soo
Lee, Kyung-Hun
Park, Se Hoon
Song, Eun-Kee
Jung, Soo-A
Lee, NaMi
Kim, Yeul Hong
Cho, Jae Yong
Bang, Yung-Jue
Funding for this research was provided by:
Hanmi Pharmaceutical Co., Ltd.
Article History
Received: 18 December 2018
Accepted: 27 March 2019
First Online: 3 April 2019
Compliance with ethical standards
:
: Yung-Jue Bang has served in consultant/advisory board roles for AstraZeneca, Novartis, Genentech/Roche, MSD, Bayer, BMS, Eli Lilly, Merck Serono, Taiho, Daiichi-Sankyo, Astellas, BeiGene, Green Cross, Samyang Biopharmaceuticals and Hanmi, and has received research grants from AstraZeneca, Novartis, Genentech/Roche, MSD, Merck Serono, Bayer, GSK, BMS, Pfizer, Eli Lilly, Boeringer-Ingelheim, MacroGenics, Boston Biomedical, FivePrime, CKD Pharma, Ono, Taiho, Takeda, BeiGene, Green Cross, Curis, Daiichi Sankyo and Astellas. Soo-A Jung and NaMi Lee are employees of Hanmi Pharmaceutical Co., Ltd., Seoul, South Korea. The other authors declare no conflicts of interest.
: All procedures followed were in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines and the study was approved by the Institutional Review Board of each participating center. All patients provided written informed consent before enrollment.
Free to read: This content has been made available to all.